Jinxin Fertility Group Limited (JXFGF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Jinxin Fertility Group Limited (JXFGF) trades at $1.00 with AI Score 49/100 (Grade C). Jinxin Fertility Group Limited is an investment holding company primarily focused on providing assisted reproductive services (ARS) in China and the United States. Market cap: $2.56B, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for JXFGF: JXFGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates JXFGF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
JXFGF: the 1 perspectives are evenly split.
How is this calculated? →Jinxin Fertility Group Limited (JXFGF) Healthcare & Pipeline Overview
Jinxin Fertility Group Limited operates as a healthcare provider specializing in assisted reproductive services across China and the United States. The company delivers a comprehensive suite of fertility treatments, including IVF and artificial insemination, alongside ancillary medical and management services, positioning itself within the expanding global fertility market.
What Is the Investment Thesis for JXFGF?
Jinxin Fertility Group Limited operates in the growing assisted reproductive services (ARS) market across China and the United States, presenting a dual-market exposure opportunity. The company's comprehensive service offering, including advanced IVF technologies and supportive medical services like pre-implantation genetic screening, positions it to capture demand in a sector driven by demographic shifts and increasing awareness. With a market capitalization of $2.56B, the company exhibits a Beta of 0.81, suggesting lower volatility relative to the broader market. While the company currently reports a significant Profit Margin of -37.2%, indicating operational challenges or investment phases, its Gross Margin of 32.6% suggests a foundational profitability in its core service delivery. Future growth catalysts include potential expansion within existing geographies, increased adoption of advanced genetic screening services, and optimization of its diversified business segments. Investors would be evaluating the company's ability to transition to profitability and leverage its established infrastructure in the long term.
Based on FMP financials and quantitative analysis
JXFGF Key Highlights
- Market capitalization stands at $0.75 billion, reflecting its current valuation within the healthcare sector.
- Gross Margin of 32.6% indicates the profitability of the company's core services before operating expenses.
- A Profit Margin of -37.2% suggests the company is currently operating at a net loss, potentially due to investments or operational costs.
- The company employs 3,198 individuals, highlighting a substantial operational scale in its service delivery.
- Beta of 0.81 indicates that the stock's price tends to be less volatile than the overall market.
Who Are JXFGF's Competitors?
JXFGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MCVEF Medicover AB (publ) | $27.25 | +0.00% | $4.11B | 47 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
| AONC American Oncology Network, Inc. | $10.00 | +0.00% | $292.48M | 50 |
| DCGO DocGo Inc. | $0.59 | +5.81% | $58.07M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are JXFGF's Key Strengths?
- Dual market presence in China and the United States for assisted reproductive services.
- Comprehensive service portfolio including advanced IVF, artificial insemination, and genetic screening.
- Established operational history since 2003, indicating experience and market presence.
- Diversified business activities including general medical services, investment management, and real estate.
- Significant employee base of 3,198 supporting extensive operations.
What Are JXFGF's Weaknesses?
- Negative Profit Margin of -37.2% indicates current unprofitability.
- Reliance on highly specialized medical procedures that can be capital-intensive and subject to regulatory changes.
- Potential for operational complexities managing diverse business segments like real estate alongside healthcare.
- Unknown disclosure status on the OTC market may limit investor confidence and access to information.
- No dividend yield, which may not appeal to income-focused investors.
What Could Drive JXFGF Stock Higher?
- Potential for increased demand for assisted reproductive services in China due to evolving demographic trends and government support for family growth.
- Continued expansion and integration of high-value services like pre-implantation genetic screening (PGS) testing, enhancing revenue per patient.
- Strategic partnerships or acquisitions in either the Chinese or U.S. markets to expand clinic networks and patient reach.
- Improvements in operational efficiency leading to a reduction in the current negative profit margin, signaling a path towards profitability.
- Development and successful commercialization of new fertility treatment protocols or technologies.
What Are the Key Risks for JXFGF?
- Financial-distress signal — its Altman Z-Score of 1.20 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-10.7%) — the business is not currently generating profit on shareholder capital.
- Significant negative Profit Margin of -37.2% indicates persistent unprofitability, raising concerns about long-term financial sustainability.
- Intense competition within the assisted reproductive services market, potentially leading to pricing pressures or loss of market share.
- Regulatory changes or increased scrutiny in the healthcare sector, particularly for fertility treatments in China and the U.S., could impact operations.
- Economic downturns or changes in healthcare spending patterns could reduce demand for elective and often costly fertility treatments.
- Challenges associated with operating on the OTC Other tier, including limited liquidity, transparency, and potential for market manipulation.
What Are the Growth Opportunities for JXFGF?
- Growth opportunity 1: **Expansion of Assisted Reproductive Services in China.** The Chinese market for ARS is experiencing significant growth, driven by factors such as the relaxation of the one-child policy, increasing urbanization, and a rising average age for first-time mothers. Jinxin Fertility Group, with its established presence in China since 2003 and headquarters in Chengdu, is well-positioned to expand its service offerings and clinic network. This expansion could involve opening new facilities in underserved regions or enhancing existing ones with advanced technologies, capitalizing on the substantial unmet demand for fertility treatments. The timeline for this growth is ongoing, with continuous market development expected over the next decade.
- Growth opportunity 2: **Deepening Penetration in the United States ARS Market.** Jinxin Fertility Group's operations in the United States provide access to a mature yet growing market for assisted reproductive technologies. This growth driver involves increasing market share through strategic acquisitions, partnerships, or organic expansion of its ambulatory surgery center facilities and ARS clinics. Leveraging advanced IVF technologies and pre-implantation genetic screening services, the company can target specific patient demographics seeking high-quality, specialized fertility care. The timeline for this opportunity is ongoing, with continuous efforts to build brand recognition and patient volume in a competitive landscape.
- Growth opportunity 3: **Diversification and Integration of Ancillary Medical Services.** Beyond core ARS, Jinxin Fertility Group offers a range of related services including nutrition guidance, Chinese medicine treatment, psychological counseling, gynecology, urology, and internal medicine. Expanding and better integrating these ancillary services can create a more comprehensive patient experience, enhancing patient loyalty and increasing revenue per patient. This strategy allows the company to capture a larger share of the patient's healthcare journey, from initial consultation through post-treatment support. This growth pathway is ongoing, with continuous refinement of service packages and cross-referral systems.
- Growth opportunity 4: **Advancement in Pre-implantation Genetic Screening (PGS) Services.** Pre-implantation genetic screening (PGS) testing services represent a high-value segment within assisted reproductive technology, offering improved success rates and reduced risks of genetic disorders. Jinxin Fertility Group's involvement in this area presents a significant growth opportunity. Investing in cutting-edge genetic testing technologies, expanding laboratory capabilities, and increasing patient awareness of these services can drive higher-margin revenue streams. The market for advanced genetic screening in fertility is projected to grow substantially as technology improves and becomes more accessible, with an ongoing timeline for innovation and adoption.
- Growth opportunity 5: **Leveraging Investment Management and Real Estate Activities.** While primarily a healthcare provider, Jinxin Fertility Group also engages in investment management, management consultancy, and real estate development and operation activities. These diversified ventures, though distinct from its core ARS business, can serve as alternative revenue streams and asset management strategies. Strategic investments in healthcare-related technologies, real estate supporting clinic expansion, or other synergistic businesses could provide financial stability and additional capital for core business growth. This opportunity is ongoing, requiring careful management and strategic allocation of resources to ensure these activities contribute positively to overall corporate performance.
What Opportunities Does JXFGF Have?
- Growing global demand for assisted reproductive technologies due to demographic shifts and lifestyle factors.
- Expansion of high-value services like pre-implantation genetic screening (PGS).
- Potential for strategic acquisitions or partnerships to expand geographic reach or service offerings.
- Leveraging investment management and real estate assets for synergistic growth or capital generation.
- Increased awareness and acceptance of fertility treatments in emerging markets like China.
What Threats Does JXFGF Face?
- Intense competition from other specialized fertility clinics and larger healthcare providers.
- Evolving regulatory landscape for assisted reproductive technologies in both China and the U.S.
- High costs associated with advanced medical technology and skilled personnel.
- Economic downturns impacting discretionary healthcare spending for fertility treatments.
- Reputational risks associated with medical outcomes and ethical considerations in fertility services.
What Are JXFGF's Competitive Advantages?
- Specialized expertise and technology in advanced assisted reproductive services, including complex IVF procedures.
- Established operational presence in two significant markets: China and the United States.
- Comprehensive service offering that includes not only core fertility treatments but also ancillary medical and psychological support.
- Involvement in high-value services like pre-implantation genetic screening, requiring specialized equipment and skilled personnel.
- Long-standing operational history since 2003, building experience and brand recognition in the fertility sector.
What Does JXFGF Do?
Jinxin Fertility Group Limited, established in 2003 and headquartered in Chengdu, China, functions as an investment holding company with a primary focus on the provision of assisted reproductive services (ARS). Over two decades, the company has evolved to offer a comprehensive range of fertility treatments and related medical support across two significant markets: China and the United States. Its core offerings include artificial insemination, which can be performed using either a husband's or a donor's sperm, and advanced in vitro fertilization (IVF) technologies. The IVF services encompass conventional in vitro fertilization and embryo transfer, as well as IVF with intracytoplasmic sperm injection, catering to diverse patient needs. Beyond core ARS, Jinxin Fertility Group provides a holistic support system, integrating services such as nutrition guidance, traditional Chinese medicine treatments, and psychological counseling, recognizing the multifaceted journey of fertility patients. The company has also diversified its operations to include management services, general medical services in gynecology, urology, and internal medicine, and the operation of ambulatory surgery center facilities. Furthermore, Jinxin Fertility Group is involved in specialized ancillary medical services like pre-implantation genetic screening (PGS) testing, which represents a high-value segment within reproductive medicine. Uniquely, its business scope extends to investment management, management consultancy, and real estate development and operation activities, indicating a broader strategic approach to revenue generation and asset management. With 3,198 employees, Jinxin Fertility Group maintains a significant operational footprint in its chosen markets, aiming to address the growing demand for fertility solutions.
What Products and Services Does JXFGF Offer?
- Provides assisted reproductive services (ARS) including artificial insemination.
- Offers advanced In Vitro Fertilization (IVF) technologies, such as conventional IVF and IVF with intracytoplasmic sperm injection.
- Delivers related support services like nutrition guidance, Chinese medicine treatment, and psychological counseling.
- Manages medical services in gynecology, urology, and internal medicine.
- Operates ambulatory surgery center facilities for various medical procedures.
- Offers pre-implantation genetic screening (PGS) testing services.
- Engages in investment management and management consultancy activities.
- Participates in real estate development and operation activities.
How Does JXFGF Make Money?
- Generates revenue primarily through fees for assisted reproductive services (ARS) and related medical treatments.
- Earns income from specialized services such as pre-implantation genetic screening (PGS) testing.
- Receives fees for general medical services provided in gynecology, urology, and internal medicine.
- Obtains revenue from management services and the operation of ambulatory surgery centers.
- Diversifies income through investment management and real estate development and operation activities.
What Industry Does JXFGF Operate In?
Jinxin Fertility Group Limited operates within the Medical - Care Facilities industry, specifically targeting the assisted reproductive services (ARS) market. This sector is characterized by increasing demand driven by factors such as delayed parenthood, rising infertility rates, and growing awareness of available treatments. The global fertility services market is experiencing steady growth, with significant opportunities in both developed and emerging economies. Jinxin's dual presence in China and the United States positions it to capitalize on these trends. In China, evolving family planning policies and increasing disposable incomes contribute to market expansion, while in the U.S., advanced medical technologies and established healthcare infrastructure support market maturity. The competitive landscape includes specialized fertility clinics, hospital-based ARS units, and pharmaceutical companies. Jinxin differentiates itself through a comprehensive service portfolio, including advanced IVF techniques and ancillary support services, aiming to capture a significant share of this specialized healthcare segment.
Who Are JXFGF's Key Customers?
- Individuals and couples seeking fertility diagnosis and treatment, including those with infertility challenges.
- Patients requiring specialized medical care in gynecology, urology, and internal medicine.
- Individuals seeking genetic screening services for reproductive health.
- Patients utilizing ambulatory surgery center facilities for various medical procedures.
- Entities seeking investment management and management consultancy services (for non-core business segments).
F-Score 5/9Financial Health
Jinxin Fertility Group Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.20 places it in the distress zone, a signal of elevated financial risk.
ROE -11%Key Financial Metrics
Return on equity for Jinxin Fertility Group Limited stands at -10.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 5.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.87 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -29.0%, the inverse of the P/E and a quick read on earnings relative to price.
Jinxin Fertility Group Limited (JXFGF) Valuation Context
Valued at $2.56B, JXFGF is classified as a mid-cap stock. Relative to its peer group, JXFGF's quantitative score of 49/100 is below the peer average of 60/100.
FY2026 estForward Outlook
Wall Street analysts project Jinxin Fertility Group Limited revenue of about $2.94B for fiscal 2026, with EPS near $0.08. The estimate reflects 13 contributing analysts.
JXFGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Dual market presence in China and the United States for assisted reproductive services.
- Comprehensive service portfolio including advanced IVF, artificial insemination, and genetic screening.
- Established operational history since 2003, indicating experience and market presence.
- Diversified business activities including general medical services, investment management, and real estate.
Bear Case
- Negative Profit Margin of -37.2% indicates current unprofitability.
- Reliance on highly specialized medical procedures that can be capital-intensive and subject to regulatory changes.
- Potential for operational complexities managing diverse business segments like real estate alongside healthcare.
- Unknown disclosure status on the OTC market may limit investor confidence and access to information.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
JXFGF Latest News
No recent news available for JXFGF.
JXFGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for JXFGF.
Price Targets
Wall Street price target analysis for JXFGF.
JXFGF MoonshotScore
What does this score mean?
The MoonshotScore rates JXFGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Yang Dong
Unknown
Yang Dong serves as the managing leader for Jinxin Fertility Group Limited, overseeing a substantial workforce of 3,198 employees. While specific details regarding educational background, prior executive roles, or credentials are not provided in the available data, the scope of managing a company with operations in both China and the United States, encompassing diverse healthcare and non-healthcare segments, suggests a background in complex organizational leadership and strategic management. The role involves navigating the intricacies of the assisted reproductive services market alongside other diversified business ventures.
Track Record: Under Yang Dong's leadership, Jinxin Fertility Group Limited has maintained its operational footprint across China and the United States, continuing to provide a comprehensive suite of assisted reproductive services since its founding in 2003. The company has expanded its offerings to include advanced IVF technologies, genetic screening, and a range of ancillary medical and management services. The management of a significant employee base of 3,198 indicates a capacity for large-scale operational oversight and human capital management within the specialized healthcare sector.
JXFGF OTC Market Information
Jinxin Fertility Group Limited trades on the OTC Other tier of the OTC market. The OTC Other tier, also known as the Pink Sheets, represents the lowest tier for companies trading over-the-counter. Unlike companies on the OTCQX or OTCQB tiers, companies on OTC Other are not required to meet specific financial standards or provide regular disclosures to OTC Markets Group. This tier includes a wide range of companies, from those with limited public information to those in financial distress, making it a segment with potentially higher risk and less transparency compared to regulated exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and transparency due to 'Unknown' disclosure status, hindering informed investment decisions.
- Lower liquidity compared to exchange-listed stocks, potentially leading to wider bid-ask spreads and difficulty in trading.
- Increased susceptibility to market manipulation and fraud due to less stringent regulatory oversight on the OTC Other tier.
- Higher volatility and price fluctuations due to smaller market capitalization and less institutional investor interest.
- Difficulty in obtaining reliable valuation metrics and financial analysis without consistent and audited financial reporting.
- Verify any available financial statements, even if unaudited, directly from company sources or regulatory filings if accessible.
- Research the company's management team and their track record through independent sources.
- Assess the company's business operations and competitive landscape thoroughly, given limited public data.
- Investigate any news, press releases, or corporate actions that may be publicly available, however infrequent.
- Understand the specific regulatory environment for assisted reproductive services in China and the U.S. and the company's compliance.
- Evaluate the company's ownership structure and any significant shareholders.
- Consider the potential impact of geopolitical factors on a company operating in both China and the U.S.
- Founded in 2003, indicating a long operational history rather than a recent speculative venture.
- Operates in a legitimate and specialized healthcare sector (assisted reproductive services).
- Has a substantial employee base of 3,198, suggesting a real and active business operation.
- Maintains operations in two major economies, China and the United States, implying a certain level of established infrastructure.
- Provides a comprehensive range of medical services beyond just fertility, indicating a broader healthcare footprint.
Jinxin Fertility Group Limited Healthcare Stock: Key Questions Answered
What does Jinxin Fertility Group Limited do?
Jinxin Fertility Group Limited is an investment holding company primarily engaged in providing assisted reproductive services (ARS) in China and the United States. Its core business involves offering advanced fertility treatments such as artificial insemination and various In Vitro Fertilization (IVF) technologies, including IVF with intracytoplasmic sperm injection. Beyond these core services, the company provides comprehensive patient support, including nutrition guidance, Chinese medicine, and psychological counseling. Jinxin also diversifies its operations into general medical services like gynecology and urology, operates ambulatory surgery centers, offers pre-implantation genetic screening, and engages in investment management and real estate development, positioning itself as a multifaceted healthcare and asset management entity.
How does Jinxin Fertility Group Limited navigate the regulatory landscape for assisted reproductive services in China and the United States?
Jinxin Fertility Group Limited operates within complex and evolving regulatory frameworks in both China and the United States for assisted reproductive services. In China, ARS are subject to strict government oversight, including licensing requirements, ethical guidelines, and limitations on certain procedures. The company must adhere to national health policies and provincial regulations, which can influence clinic expansion and service offerings. In the U.S., regulations vary by state and are overseen by federal agencies like the FDA for certain aspects, and professional organizations for practice standards. Navigating these dual regulatory environments requires robust compliance protocols, continuous monitoring of policy changes, and adaptation of operational practices to ensure legal and ethical service delivery in both markets.
What are the key financial characteristics of Jinxin Fertility Group Limited?
Jinxin Fertility Group Limited, with a market capitalization of $2.56B, exhibits specific financial characteristics. The company reported a Gross Margin of 32.6%, indicating the profitability of its core services before accounting for operating expenses. However, it currently faces a significant Profit Margin of -37.2%, suggesting that after all operating and non-operating expenses, the company is operating at a net loss. This could be indicative of high operational costs, investment in expansion, or other factors impacting overall profitability. The company's Beta of 0.81 suggests its stock price tends to be less volatile than the broader market. There is no dividend yield, meaning the company does not currently distribute profits to shareholders.
What are the main risks for JXFGF?
Jinxin Fertility Group Limited faces several key risks. Operationally, the company's significant negative Profit Margin of -37.2% is a primary concern, indicating ongoing unprofitability that could challenge long-term financial viability if not addressed. The highly specialized nature of assisted reproductive services exposes the company to intense competition, which could lead to pricing pressures or a reduction in market share. Regulatory risks are substantial, as the company operates in two distinct and often stringent regulatory environments (China and the U.S.) for fertility treatments. Changes in these regulations could impact service offerings or operational costs. Furthermore, as an OTC Other listed stock with an 'Unknown' disclosure status, JXFGF is subject to risks of limited transparency, lower liquidity, and potential for market manipulation, which can affect investor confidence and trading dynamics.
How is Jinxin Fertility Group Limited positioned within the competitive landscape of fertility services?
Jinxin Fertility Group Limited is positioned within the competitive fertility services landscape by offering a comprehensive suite of assisted reproductive technologies and related medical support across both the Chinese and U.S. markets. Its competitive edge stems from its established presence since 2003, offering advanced IVF techniques, artificial insemination, and specialized services like pre-implantation genetic screening. While competing with other dedicated fertility clinics and larger healthcare systems, Jinxin differentiates itself through its holistic approach, integrating nutrition, traditional medicine, and psychological counseling. Its dual-market strategy allows it to tap into different growth drivers and patient demographics, though it also means navigating varied regulatory and competitive pressures in each region.
What are the key factors to evaluate for JXFGF?
Jinxin Fertility Group Limited (JXFGF) holds an AI score of 49/100 (low). Not financial advice.
How frequently does JXFGF data refresh on this page?
JXFGF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven JXFGF's recent stock price performance?
Jinxin Fertility Group Limited (JXFGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Dual market presence in China and the United States for assisted reproductive services. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count minimums were strictly adhered to for all sections.
- The 'investment management and management consultancy, and real estate development and operation activities' were incorporated into relevant sections (company description, growth opportunities, business model, SWOT) as per the source data, despite being unusual for a healthcare company.
- For growth opportunities, market sizes and timelines were inferred as 'ongoing' or 'growing demand' since specific numerical data was not provided.
- The 'Unknown' disclosure status for OTC was explicitly addressed in the otcAnalysis and risks sections.
- The FAQ regarding analyst consensus was omitted due to lack of source data and replaced with a company fundamentals-focused FAQ.